The Role of Plasminogen-Plasmin System in Cancer
Authors:
- Hau C. KwaanHKHau C. Kwaan
- Brandon McMahonBMBrandon McMahon
- 28 February 2009
- book chapter
- Published by Springer Nature
- Vol. 148, 43-66
Abstract
Components of the plasminogen-plasmin system participate in a wide variety of physiologic and pathologic processes, including tumor growth, invasion and metastasis, through their effect on angiogenesis and cell migration. These components are found in most tumors and their expression not only signifies their function but also carries a prognostic value. Their expression is in turn modulated by cytokines and growth factors, many of which are up-regulated in cancer. Though both tPA and uPA are expressed in tumor cells, uPA with its receptor (uPAR) is mostly involved in cellular functions, while tPA with its receptor Annexin II on endothelial surface, regulates intravascular fibrin deposition. Among the inhibitors of fibrinolysis, PAI-1 is a major player in the pathogenesis of many vascular diseases as well as in cancer. Therapeutic interventions, either using plasminogen activators or experimental inhibitor agents against PAI-1, have shown encouraging results in experimental tumors but not been verified clinically.Keywords
This publication has 108 references indexed in Scilit:
- Monomer–dimer dynamics and distribution of GPI-anchored uPAR are determined by cell surface protein assembliesJournal of Cell Biology, 2007
- uPAR-induced cell adhesion and migration: vitronectin provides the keyJournal of Cell Biology, 2007
- Prognostic Value of PAI1 in Invasive Breast Cancer: Evidence That Tumor-Specific Factors Are More Important Than Genetic Variation in Regulating PAI1 ExpressionCancer Epidemiology, Biomarkers & Prevention, 2006
- The undecided serpinThe FEBS Journal, 2005
- Increased circulating levels of thrombin‐activatable fibrinolysis inhibitor in lung cancer patientsAmerican Journal of Hematology, 2004
- Thrombin-Activable Fibrinolysis Inhibitor Levels in the Acute Phase of Ischemic StrokeStroke, 2003
- Clinical Relevance of Urokinase-Type Plasminogen Activator, Its Receptor, and Its Inhibitor Type 1 in Endometrial CancerGynecologic Oncology, 2001
- High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinomaCancer, 1997
- Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model.Journal of Clinical Investigation, 1995
- The plasminogen-plasmin system in malignancyCancer and Metastasis Reviews, 1992